A Patient Advocacy Perspective on Expanding Access to CAR T-cell Therapy

ONCOLife presents an exclusive interview with Lorna Warick, CEO of Lymphoma Coalition. In this session, we explore the critical role of patient advocacy in improving access to CAR T-cell therapy — a life-changing treatment for patients with aggressive and treatment-resistant blood cancers. Lorna Warick offers key insights into the real-world barriers patients face, from delayed referrals and lack of information to logistical and financial challenges. You can also follow this interview on LinkedIn using this link:>>>

She emphasizes the importance of culturally sensitive, evidence-based communication and the urgent need for more coordinated efforts among stakeholders to ensure equitable access. We also discuss the CAR T Vision initiative’s ambitious goal to double the proportion of eligible patients treated by 2030 and how global advocacy organizations are mobilizing to turn that vision into reality.

Some of the main topics in this interview include:

✔️ The real-world barriers patients face in accessing CAR T
✔️ The importance of culturally sensitive, evidence-based information
✔️ How global advocacy can drive change in care pathways and policy
✔️ The goal to double patient access to CAR T-cell therapy by 2030